Cesca Receives Notice of Allowance for U.S. Patent Application Covering a Novel Method of Cell Separation
03 October 2017 - 10:00PM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that the U.S. Patent and Trademark Office (USPTO)
has issued a Notice of Allowance regarding the company’s pending
application for a patent covering its proprietary method for
separating rare, therapeutically critical target cells from blood,
bone marrow, leukapheresis product, and other cell sources, while
maintaining the viability of the cells under asceptic conditions.
This advanced cell separation technology, known as
Buoyancy-Activated Cell Separation, or BACS, is key to the ongoing
development of Cesca’s CAR-TXpress™ platform.
When issued, this will be Cesca’s second patent
in a series relating to its X-BACS technology. On July 28, 2017,
Cesca announced that SynGen, Inc., which the company acquired on
July 10, 2017, had been awarded a U.S. patent (No. 9,695,394, or
the ‘394 patent) covering the X-BACS apparatus. The ‘394 patent
also allows for the automated isolation of cells with low density
surface antigens, which was previously a major cellular
manufacturing challenge.
“This Notice of Allowance further strengthens
our intellectual property position as we advance development of our
novel CAR-TXpress™ solution for the automated manufacture of CAR-T
cells,” said Chris Xu, Cesca’s chief executive officer. “CAR-T
represents the future of cancer treatment, yet we believe speed,
cost and consistency will likely emerge as significant industry
challenges. With the X-BACS technology embedded in CAR-TXpress,
manufacturers will be able to improve the yield and consistency of
CAR-T cells in less time and at a lower cost. We look forward to
partnering with some of the most innovative biopharmaceutical
companies in the field to enhance the commercial viability of these
ground-breaking treatments.”
“We are pleased that the USPTO continues to
recognize the unique attributes of the X-BACS technology,” said
Philip Coelho, chief technology officer of ThermoGenesis and
co-inventor of the allowed patent. “In clinical trials, CAR-T
immunotherapies continue to show unprecedented results where
currently available treatments have failed, but the delivery of
CAR-T represents a significant departure from legacy
biopharmaceutical business models. We are eager to leverage X-BACS
to make these expensive and time-consuming treatments more broadly
available to patients in need.”
The X-BACS technology employs microscopic
bubbles to isolate a specific cell type from a complex mixture of
cells, such as blood. These microbubbles bear antibodies on their
surface, enabling them to bind specifically to a single desired
target cell type. When coated with microbubbles, the target cells
float to the top of the host liquid, while non-target cells sink to
the bottom - a process that can be accelerated by centrifugation.
Subsequent collection of the floating target cell layer and release
of the cells from their microbubbles provides a highly-purified
preparation of just the cells of interest, with high recovery
efficiency while retaining cell viability.
About Cesca Therapeutics Inc.Cesca is a leading
regenerative medicine company that develops, commercializes and
markets a range of automated technologies for cell-based
therapeutics. Its device division, ThermoGenesis, provides a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. Cesca is also
leveraging its proprietary AutoXpress® technology platform to
develop autologous stem cell-based therapies that address
significant unmet needs in the vascular, cardiology and orthopedic
markets.
Forward-Looking StatementThe statements
contained herein may include statements of future expectations and
other forward-looking statements that are based on management’s
current views and assumptions and involve known and unknown risks
and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics’ annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. Wendy
SamfordCesca Therapeutics Inc.
916-858-5191ir@cescatherapeutics.com
Investor Contact: Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2024 to May 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From May 2023 to May 2024